Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Pia Amato

Showing results (81-90 of 330) with videos related to

Pageof 33
Sort By:
Journal of Neurology|August 10, 2025
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensusMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Journal of Neurology|November 27, 2012
Treatment of cognitive impairment in multiple sclerosis: position paperMaria Pia Amato, Dawn Langdon, Xavier Montalban, et al.
Plos One|October 19, 2013
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS studyFrancesco Patti, Vincenzo Brescia Morra, Maria Pia Amato, et al.
Journal of Neurology|May 24, 2022
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Frontiers in Neurology|March 5, 2024
Priority setting: women's health topics in multiple sclerosisLindsay Ross, Marcia Finlayson, Maria Pia Amato, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 30, 2026
Relapse-associated worsening in apolipoprotein E ε4 carriers with relapsing multiple sclerosisEmilio Portaccio, Maria Grazia Aprea, Ermelinda De Meo, et al.
BMC Neurology|October 18, 2011
Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) studyStefano Bastianello, Elisabetta Giugni, Maria Pia Amato, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 29, 2011
Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II)Francesco Patti, Maria Pia Amato, Maria Trojano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 3, 2020
Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosisMaria Pia Amato, Benedetta Goretti, Vincenzo Brescia Morra, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 16, 2015
Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measuresAntonio Giorgio, Maria Laura Stromillo, Alessandro De Leucio, et al.
Pageof 33

Showing results (81-90 of 330) with videos related to

Sort By:
Pageof 33
Journal of Neurology|August 10, 2025
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensusMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Journal of Neurology|November 27, 2012
Treatment of cognitive impairment in multiple sclerosis: position paperMaria Pia Amato, Dawn Langdon, Xavier Montalban, et al.
Plos One|October 19, 2013
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS studyFrancesco Patti, Vincenzo Brescia Morra, Maria Pia Amato, et al.
Journal of Neurology|May 24, 2022
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Frontiers in Neurology|March 5, 2024
Priority setting: women's health topics in multiple sclerosisLindsay Ross, Marcia Finlayson, Maria Pia Amato, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 30, 2026
Relapse-associated worsening in apolipoprotein E ε4 carriers with relapsing multiple sclerosisEmilio Portaccio, Maria Grazia Aprea, Ermelinda De Meo, et al.
BMC Neurology|October 18, 2011
Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving interferon β-1a in the COGnitive Impairment in MUltiple Sclerosis (COGIMUS) studyStefano Bastianello, Elisabetta Giugni, Maria Pia Amato, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 29, 2011
Longitudinal changes in social functioning in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II)Francesco Patti, Maria Pia Amato, Maria Trojano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 3, 2020
Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosisMaria Pia Amato, Benedetta Goretti, Vincenzo Brescia Morra, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|January 16, 2015
Appraisal of brain connectivity in radiologically isolated syndrome by modeling imaging measuresAntonio Giorgio, Maria Laura Stromillo, Alessandro De Leucio, et al.
Pageof 33